Your browser doesn't support javascript.
loading
ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies
Jun Siong Low; Josipa Jerak; M. Alejandra Tortorici; Matthew McCallum; Dora Pinto; Antonino Cassotta; Mathilde Foglierini; Federico Mele; Rana Abdelnabi; Birgit Weynand; Julia Noack; Martin Montiel-Ruiz; Siro Bianchi; Fabio Benigni; Nicole Sprugasci; Anshu Joshi; John E Bowen; Alexandra C. Walls; David Jarrossay; Diego Morone; Philipp Paparoditis; Christian Garzoni; Paolo Ferrari; Alessandro Ceschi; Johan Neyts; Lisa A. Purcell; Gyorgy Snell; Davide Corti; Antonio Lanzavecchia; David Veesler; Federica Sallusto.
Afiliação
  • Jun Siong Low; Institute of Microbiology, ETH Zurich, 8093 Zurich, Switzerland
  • Josipa Jerak; Institute of Microbiology, ETH Zurich, 8093 Zurich, Switzerland
  • M. Alejandra Tortorici; Department of Biochemistry, University of Washington, Seattle WA, 98195, USA
  • Matthew McCallum; Department of Biochemistry, University of Washington, Seattle WA, 98195, USA
  • Dora Pinto; Humabs BioMed SA, subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
  • Antonino Cassotta; Institute for Research in Biomedicine, Universita della Svizzera italiana, 6500 Bellinzona, Switzerland
  • Mathilde Foglierini; Institute for Research in Biomedicine, Universita della Svizzera italiana, 6500 Bellinzona, Switzerland
  • Federico Mele; Institute for Research in Biomedicine, Universita della Svizzera italiana, 6500 Bellinzona, Switzerland
  • Rana Abdelnabi; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuve
  • Birgit Weynand; KU Leuven Department of Imaging and Pathology, Translational Cell and Tissue Research, B-18 3000
  • Julia Noack; Humabs BioMed SA, subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
  • Martin Montiel-Ruiz; Humabs BioMed SA, subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
  • Siro Bianchi; Humabs BioMed SA, subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
  • Fabio Benigni; Humabs BioMed SA, subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
  • Nicole Sprugasci; Humabs BioMed SA, subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
  • Anshu Joshi; Department of Biochemistry, University of Washington, Seattle WA, 98195, USA
  • John E Bowen; Department of Biochemistry, University of Washington, Seattle WA, 98195, USA
  • Alexandra C. Walls; Department of Biochemistry, University of Washington, Seattle WA, 98195, USA
  • David Jarrossay; Institute for Research in Biomedicine, Universita della Svizzera italiana, 6500 Bellinzona, Switzerland
  • Diego Morone; Institute for Research in Biomedicine, Universita della Svizzera italiana, 6500 Bellinzona, Switzerland
  • Philipp Paparoditis; Institute for Research in Biomedicine, Universita della Svizzera italiana, 6500 Bellinzona, Switzerland
  • Christian Garzoni; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, 22 Switzerland
  • Paolo Ferrari; Faculty of Biomedical Sciences, Universita della Svizzera italiana, 6900 Lugano, Switzerland
  • Alessandro Ceschi; Faculty of Biomedical Sciences, Universita della Svizzera italiana, 6900 Lugano, Switzerland
  • Johan Neyts; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuve
  • Lisa A. Purcell; Humabs BioMed SA, subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
  • Gyorgy Snell; Humabs BioMed SA, subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
  • Davide Corti; Humabs BioMed SA, subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
  • Antonio Lanzavecchia; National Institute of Molecular Genetics, 20122 Milano, Italy
  • David Veesler; Department of Biochemistry, University of Washington, Seattle WA, 98195, USA
  • Federica Sallusto; Institute of Microbiology, ETH Zurich, 8093 Zurich, Switzerland
Preprint em En | PREPRINT-BIORXIV | ID: ppbiorxiv-486377
ABSTRACT
Coronaviruses use diverse Spike (S) glycoproteins to attach to host receptors and fuse with target cells. Using a broad screening approach, we isolated from SARS-CoV-2 immune donors seven monoclonal antibodies (mAbs) that bind to all human alpha and beta coronavirus S proteins. These mAbs recognize the fusion peptide and acquire high affinity and breadth through somatic mutations. Despite targeting a conserved motif, only some mAbs show broad neutralizing activity in vitro against alpha and beta coronaviruses, including Omicron BA.1 variant and bat WIV-1, and reduce viral titers and pathology in vivo. Structural and functional analyses show that the fusion peptide-specific mAbs bind with different modalities to a cryptic epitope which is concealed by prefusion-stabilizing 2P mutations and becomes exposed upon binding of ACE2 or ACE2-mimicking mAbs. This study identifies a new class of pan-coronavirus neutralizing mAbs and reveals a receptor-induced conformational change in the S protein that exposes the fusion peptide region.
Licença
cc_no
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint